价格

Mabwell (Shanghai) Bioscience Co., Ltd.

ACTIVE

Bldg 3, No 576, Libing Rd, Pudong New District, 上海市（市辖区）, 上海市, 中国www.mabwell.comPublic1,491 名员工成立于: 2017-05-12

隶属于 langrun shenzhen equity investment fund enterprise lp

概览

试验阶段分布

阶段

试验数

占比

1 期

61.5%

2 期

23.1%

3 期

15.4%

试验状态分布

进行中（未招募）

5.8%

已完成

25.0%

尚未招募

15.4%

招募中

40.4%

暂停

1.9%

Unknown

11.5%

药物批准

暂无批准数据

资讯

Bone Metastasis Treatment Pipeline Shows Robust Development with 10+ Companies Advancing Novel Therapies

- DelveInsight's 2025 pipeline analysis reveals over 10 companies developing more than 10 therapeutic candidates for bone metastasis treatment across various clinical stages. - Mabwell's MW032, a denosumab biosimilar targeting RANKL, has advanced to Phase III trials for bone metastases from solid tumors, representing the most advanced pipeline candidate. - AlaMab Therapeutics' ALMB-0168, a first-in-class monoclonal antibody targeting Cx43 protein, has received FDA orphan drug designation for osteosarcoma treatment. - Exelixis initiated a Phase II combination study of cabozantinib plus nivolumab for advanced castration-resistant prostate cancer in November 2025.

Nov 28, 2025

返回机构列表

Mabwell (Shanghai) Bioscience Co., Ltd.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（52）

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Phase I Study of 9MW4113 Injection Versus Dupixent®

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

First-in-human Study of 7MW4911 in GI Cancer

A Phase II Study of 9MW3811 in Patients With Pathological Scar

First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

药物批准

资讯

Bone Metastasis Treatment Pipeline Shows Robust Development with 10+ Companies Advancing Novel Therapies